What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?

被引:0
|
作者
Mónica Curado
Ana Sofia Caramelo
Catarina Eloy
António Polónia
机构
[1] University of Porto,Department of Pathology, Ipatimup Diagnostics, Institute of Molecular Pathology and Immunology
[2] University of Porto,I3S–Instituto de Investigação e Inovação em Saúde
[3] University of Porto,Faculty of Medicine
来源
Virchows Archiv | 2019年 / 475卷
关键词
ASCO/CAP; Breast cancer; HER2; SISH;
D O I
暂无
中图分类号
学科分类号
摘要
To evaluate the effect of the 2018 ASCO/CAP guideline in the identification of HER2-positive breast carcinomas (BC) in reflex in situ hybridization (ISH) test. A total of 592 primary invasive BC cases from before and after the publication of the updated ASCO/CAP guideline were evaluated for HER2 amplification by silver ISH according to the 2013 and 2018 guidelines. Cases were mostly (95%) HER2 equivocal by immunohistochemistry (IHC), not centrally reviewed. Other reasons for referring cases were IHC confirmation, IHC discordancy (either between needle-core-biopsy (NCB) and surgical excision specimen (SES) or between different laboratories) and IHC result unexpected for histopathologic features. Cases evaluated with the 2013 guideline (1st cohort) were 14.6% HER2-positive, decreasing significantly after the reclassification with the 2018 guideline due to the exclusion of group 2 cases without HER2 protein overexpression. Cases studied after the implementation of the 2018 guideline (2nd cohort) were 8.7% HER2-positive, a frequency that was not significantly different from the reclassification of the 1st cohort with the 2018 guideline. All cases referred for IHC confirmation had the expected ISH result. Cases with IHC discordancy between NCB and SES were ISH concordant. Only one out of 14 cases with an IHC score 3+ and classified as histological grade 1 or with a Ki67 below 10% was classified as ISH HER2-positive. The 2018 ASCO/CAP guideline resulted in a decrease of HER2-positive cases in reflex ISH test, selecting less patients for anti-HER2-targeted therapy.
引用
收藏
页码:303 / 311
页数:8
相关论文
共 50 条
  • [41] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Lei Guo
    Pei Yuan
    Jing Zhang
    Yun Ling
    Wenbin Li
    Bohui Zhao
    Jianming Ying
    Lixue Xuan
    Breast Cancer Research and Treatment, 2017, 166 : 77 - 84
  • [42] Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
    Kong, Hui
    Bai, Qianming
    Li, Anqi
    Zhou, Xiaoyan
    Yang, Wentao
    DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [43] Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
    Crespo, James
    Sun, Hongxia
    Wu, Jimin
    Ding, Qing-Qing
    Tang, Guilin
    Robinson, Melissa K.
    Chen, Hui
    Sahin, Aysegul A.
    Lim, Bora
    PLOS ONE, 2020, 15 (11):
  • [44] Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
    Hui Kong
    Qianming Bai
    Anqi Li
    Xiaoyan Zhou
    Wentao Yang
    Diagnostic Pathology, 17
  • [45] Histologic analysis according to HER2 gene status in HER2 2+invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations
    Hwang, Hye Won
    Hong, Soon Auck
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jong-Han
    Lee, Se Kyung
    Cho, Soo Youn
    Cho, Eun Yoon
    VIRCHOWS ARCHIV, 2022, 480 (04) : 749 - 758
  • [46] Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
    Xu, Bin
    Shen, Jianguo
    Guo, Wenhao
    Zhao, Wenhe
    Zhuang, Yiyu
    Wang, Linbo
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (02) : 251 - 255
  • [47] Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines
    Xu, Fang-Ping
    Wang, Kun
    Xu, Jie
    Chen, Jie
    Zhang, Yi-Fang
    Wu, Hong-Mei
    Zhang, Ming-Hui
    Long, Xiao-Xu
    Luo, Xin-Lan
    Zhang, Ke-Ping
    Lin, Dan-Yi
    Liu, Yan-Hui
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (03) : 757 - 764
  • [48] Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines
    Fang-Ping Xu
    Kun Wang
    Jie Xu
    Jie Chen
    Yi-Fang Zhang
    Hong-Mei Wu
    Ming-Hui Zhang
    Xiao-Xu Long
    Xin-Lan Luo
    Ke-Ping Zhang
    Dan-Yi Lin
    Yan-Hui Liu
    Breast Cancer Research and Treatment, 2017, 166 : 757 - 764
  • [49] Impact of the Updated 2018 ASCO/CAP HER2 Guidelines: A Retrospective Study
    Wu, Jessie
    Mullen, Brendan
    Mrkonjic, Miralem
    Turashvili, Gulisa
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 287 - 288
  • [50] Impact of the Updated 2018 ASCO/CAP HER2 Guidelines: A Retrospective Study
    Wu, Jessie
    Mullen, Brendan
    Mrkonjic, Miralem
    Turashvili, Gulisa
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 287 - 288